Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prostate cancer

Exosome RNA expression predicts high-grade disease

Nature Reviews Urology volume 13, pages 298–299 (2016)Cite this article

Subjects

A novel noninvasive urine exosome gene expression assay is able to discriminate high-grade prostate cancer from low-grade or benign disease when used in combination with standard-of-care (SOC) tests, according to data presented in JAMA Oncology.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. http://dx.doi.org/10.1001/jamaoncol.2016.0097 (2016)

Download references

Authors
  1. Louise Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stone, L. Exosome RNA expression predicts high-grade disease. Nat Rev Urol 13, 298–299 (2016). https://doi.org/10.1038/nrurol.2016.78

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.78

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer